Vyzulta - (0.024% ; Ophthalmic Solution)

Generic Name	Latanoprostene Bunod	Innovator	BAUSCH AND LOMB INC
Dosage	0.024% ; Ophthalmic Solution	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	VYZULTA™ (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
***** ******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
** *****'*	** \ **	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events